Loading...
XNAS
LFCR
Market cap241mUSD
Oct 08, Last price  
6.43USD
1D
-0.16%
1Q
35.37%
Jan 2017
-53.41%
Name

Lifecore Biomedical Inc

Chart & performance

D1W1MN
XNAS:LFCR chart
P/E
—
P/S
7.06
EPS
—
Div yield, %
—
Shrs. gr., 5y
4.98%
Rev. gr., 5y
-21.03%
Revenues
34m
-73.61%
238,527,000235,938,000238,224,000276,729,000317,552,000441,708,000476,813,000539,257,000541,099,000532,257,000524,227,000557,559,000160,066,000100,874,000111,270,000103,269,000128,261,000128,867,000129,464,59334,167,000
Net income
-6m
L-80.01%
13,542,0007,730,0003,984,0003,920,00012,696,00022,587,00019,145,00013,544,000-11,641,00010,590,00024,829,0002,122,000-38,191,000-32,294,000-116,715,000-99,563,00012,013,000-38,717,000-30,790,291-6,156,000
CFO
13m
0.00%
17,520,0009,435,0007,483,00014,469,00022,181,00021,230,00021,045,00026,155,00021,784,00029,327,00019,779,00016,020,000-17,041,00016,471,000-22,593,000-17,441,000257,000-206,00012,565,71612,565,716

Notes

No notes on this company yet
Write a private note on this company, for your eyes only

Profile

Lifecore Biomedical, Inc., together with its subsidiaries, operates as an integrated contract development and manufacturing organization that serves customers in the United States, Belgium, the Netherlands, and internationally. It provides services in the development, manufacture, aseptic fill, and finish of formulations and highly viscous sterile injectable pharmaceutical drug or medical device products in syringes, vials, and cartridges in various modalities. The company also manufactures and sells pharmaceutical-grade hyaluronic acid in bulk form, as well as for use in formulated and filled syringes and vials for injectable products used in treating various medical conditions and procedures, including ophthalmic and orthopedic applications. In addition, it offers product development services, including analytical method development and validation, formulation development, sterile filtration, process scale-up, pilot studies, stability studies, process validation, and materials production for clinical studies. The company was formerly known as Landec Corporation and changed its name to Lifecore Biomedical, Inc. in November 2022. Lifecore Biomedical, Inc. was founded in 1965 and is headquartered in Chaska, Minnesota.

Related entities

Subsidiaries (3)
CURATION FOODS, INC.
LIFECORE BIOMEDICAL OPERATING COMPANY, INC.
YUCATAN FOODS, LLC

Key people

Andrew Kenneth William Powell
Interim Independent Chairman of the Board · since 2019
President, Chief Executive Officer, Director · since 2019
Brian F. McLaughlin
Chief Financial Officer, Vice President of Finance and Administration · since 2020
Timothy P. Burgess
Senior Vice President of Supply Chain for Curation Foods · since 2019
James G. Hall
Vice President, President of Lifecore · since 2017
Parker K. Javid
Vice President, Chief Customer and Sales Officer for Curation Foods · since 2018
Independent Director · since 2019
Deborah D. Carosella
Independent Director · since 2017
Frederick Frank
Independent Director · since 1999
Katrina L. Houde
Independent Director · since 2019
Independent Director · since 2019
Independent Director
Tonia Pankopf
Independent Director · since 2012
Independent Director · since 2012
IPO date
Feb 15, 1996
Employees
689
Domiciled in
US
Incorporated in
US
Legal address
C/O CORPORATION SERVICE COMPANY
251 LITTLE FALLS DRIVE
WILMINGTON, DE 19808
US
Headquarters
2811 AIRPARK DRIVE
SANTA MARIA, CA 93455
US
Previous name
LANDEC CORPORATION

Valuation

Title
USD in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFYFYFYFY
2026‑122026‑062025‑122025‑052024‑052023‑052022‑052021‑052020‑052019‑052018‑052017‑05
Income
Revenues
Cost of revenue
Unusual Expense (Income)
NOPBT
NOPBT Margin
Operating Taxes
Tax Rate
NOPAT
Net income
Dividends
Dividend yield
Proceeds from repurchase of equity
BB yield
Debt
Debt current
Long-term debt
Deferred revenue
Other long-term liabilities
Net debt
Cash flow
Cash from operating activities
CAPEX
Cash from investing activities
Cash from financing activities
FCF
Balance
Cash
Long term investments
Excess cash
Stockholders' equity
Invested Capital
ROIC
ROCE
EV
Common stock shares outstanding
Price
Market cap
EV
EBITDA
EV/EBITDA
Interest
Interest/NOPBT